Therapie peritonealer Metastasen

Abstract

BackgroundPeritoneal carcinomatosis arising from gastrointestinal malignancies represents a major therapeutic challenge for oncological surgeons, oncologists and radiotherapists. The development of so-called multimodal therapy consisting of perioperative systemic chemotherapy, radical cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy (HIPEC) has resulted in significant prolongation of overall survival in these patients.AimSurvival data from prospective, randomized trials and register studies in recent years have established multimodal therapy as a treatment option for peritoneal metastatic colorectal as well as gastric cancer in the German guidelines. The current work on this complex topic ensures insight into the background of this topic.Materials and methodsThis paper is based on a selective literature search in the medical database PubMed on the keywords hyperthermic intraperitoneal chemotherapy, colorectal cancer, gastric cancer, multimodal therapy as well as on internal data from a reference center for the therapy of peritoneal malignancies from Germany.ResultsMultimodal therapy consisting of perioperative systemic chemotherapy, radical cytoreductive surgery, and HIPEC leads to better oncologic outcome in well-selected patients with peritoneal metastatic gastric and colorectal cancer in high-volume centers.